Publications by authors named "Mark Exley"

Claim this Profile
T
The allogeneic FAP-CAR-IL15 iNKT therapy MiNK-215 remodels the tumor stroma to enhance antitumor immunity.
Eleni Chantzoura, Efrat Altman-Sharoni, Xavier Michelet, Martyna C Popis, Magdalena Niedzielska, Mark A Exley

Cancer Immunol Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Innate iNKT cells: from biological insight to clinical impact.
Antonia Rotolo, Nicola J Mason, Mark A Exley

Front Immunol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAR-iNKT cells: redefining the frontiers of cellular immunotherapy.
Magdalena Niedzielska, Amy Chalmers, Martyna C Popis, Efrat Altman-Sharoni, Stephen Addis, Mark A Exley

Front Immunol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Broad applicability of the Goldspire™ platform for the treatment of solid tumors.
Jenny Zilberberg, Christopher Uhl, Charles B Scott, David W Andrews, Mark A Exley

Clin Immunol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy.
Carrie E Andrews, Jenny Zilberberg, Raul Perez-Olle, Mark A Exley, David W Andrews

J Neurooncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome.
Terese C Hammond, Marco A Purbhoo, Sapana Kadel, Jerome Ritz, Sarah Nikiforow, Mark A Exley

Nat Commun· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy.
Carrie E Andrews, Jenny Zilberberg, Raul Perez-Olle, Mark A Exley, David W Andrews

J Neurooncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma.
Christopher Cultrara, Christopher Uhl, Kenneth Kirby, Essam Abed Elrazaq, Amelia Zellander, Mark A Exley

J Immunother Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model.
Bindu Varghese, Lydia Lynch, Lianne E Vriend, Dobrin Draganov, Justice M Clark, Mark A Exley

Cancer Immunol Immunother· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges and Opportunities for Immunotherapeutic Intervention against Myeloid Immunosuppression in Glioblastoma.
Mark A Exley, Samantha Garcia, Amelia Zellander, Jenny Zilberberg, David W Andrews

J Clin Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma.
David W Andrews, Kevin D Judy, Charles B Scott, Samantha Garcia, Larry A Harshyne, Mark A Exley

Clin Cancer Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploiting CD1-restricted T cells for clinical benefit.
Mark A Exley, Paolo Dellabona, Giulia Casorati

Mol Immunol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A nano-engager for iNKT cells in cancer.
Mark A Exley, Thomas Gensollen, Richard S Blumberg

Nat Cancer· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Control of CD1d-restricted antigen presentation and inflammation by sphingomyelin.
Espen Melum, Xiaojun Jiang, Kristi D Baker, M Fatima Macedo, Jürgen Fritsch, Mark A Exley

Nat Immunol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
iNKT cells and hematopoietic stem cell transplantation: Two-phase activation of iNKT cells may improve outcome.
Mohammad Fereidouni, Afshin Derakhshani, Mark A Exley

Clin Immunol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression.
Dorian Stolk, Hans J van der Vliet, Tanja D de Gruijl, Yvette van Kooyk, Mark A Exley

Front Immunol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the frequency of invariant natural killer T (iNKT) cells in nasal polyps.
Mohammad Fereidouni, Afshin Derakhshani, Simon Yue, Saeed Nasseri, Reza Farid Hosseini, Mark A Exley

Clin Immunol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy.
Benjamin J Wolf, Jiyoung Elizabeth Choi, Mark A Exley

Front Immunol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells.
Eleanor Clancy-Thompson, Lestat Ali, Patrick T Bruck, Mark A Exley, Richard S Blumberg

Cancer Immunol Res· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isolation and Functional Use of Human NKT Cells.
Mark A Exley, S Brian Wilson, Steven P Balk

Curr Protoc Immunol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial.
Mark A Exley, Phillip Friedlander, Nadia Alatrakchi, Lianne Vriend, Simon Yue

Clin Cancer Res· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overview: NK-cell-based Immunotherapies: Toward & Into Clinical Trials.
Mark A Exley, Jordan S Orange

Clin Immunol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of natural killer T cells in a mouse model with spontaneous bile duct inflammation.
Elisabeth Schrumpf, Xiaojun Jiang, Sebastian Zeissig, Marion J Pollheimer, Jarl Andreas Anmarkrud, Mark A Exley

Physiol Rep· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adipose Type One Innate Lymphoid Cells Regulate Macrophage Homeostasis through Targeted Cytotoxicity.
Selma Boulenouar, Xavier Michelet, Danielle Duquette, David Alvarez, Andrew E Hogan, Mark A Exley

Immunity· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What rheumatologists need to know about innate lymphocytes.
Mark A Exley, George C Tsokos, Kingston H G Mills, Dirk Elewaut, Ben Mulhearn

Nat Rev Rheumatol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis